Chinese medical equipment manufacturer Shenzhen Mindray Bio-Medical Electronics Co.,Ltd. (300760.SZ) is planning a secondary listing in Hong Kong, with the offering expected to raise at least $1 billion. Huatai Securities and JPMorgan Chase are preparing the stock issuance. Sources indicate that additional banks may join the listing process at a later stage. Both Huatai Securities and JPMorgan Chase declined to comment, while Shenzhen Mindray Bio-Medical Electronics Co.,Ltd. has not yet responded.

As a global leading supplier of medical devices and solutions, Shenzhen Mindray Bio-Medical Electronics Co.,Ltd. possesses the most comprehensive product portfolio among domestic peers in the industry. The company's patient monitors, anesthesia machines, ventilators, defibrillators, hematology analyzers, ultrasound systems and other products all rank among the top three in global market share. The company's medical ecosystem continues to deepen clinical applications, focusing on critical care departments. In 2024, it launched the Qiyuan Critical Care Large Model, which is expected to be applied to emergency departments, anesthesiology, imaging, laboratory medicine and other departments in the future, comprehensively deploying digital intelligence in areas including assisted diagnosis and treatment, report generation and review, clinical case and knowledge retrieval, and teaching and research.